Zydus Lifesciences acquires US pharma firm Assertio for $166 million

In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166.40 million deal to acquire Assertio Holdings. The purchase includes Assertio’s essential cancer treatment, Rolvedon, and offers Zydus a rich commercial network to elevate its oncology initiatives.